PGI7 Adherence to 5-Aminosalicylic Acid (5-ASA) Therapies in Ulcerative Colitis (UC): A UK Budget Impact Analysis

aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

Sulphasalazine was developed in the 1930s, initially for use in patients with rheumatic polyarthritis. However, its modest eVects in arthritis were soon overshadowed by the striking benefits seen when the drug was given to patients with active colitis. Controlled clinical trials confirmed the early favourable impressions and established a role for sulphasalazine in the treatment of active disea...

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis

Objective(s): This study is aimed to design and synthesize a prodrug of 5-aminosalicylic acid and evaluate its ameliorative effect on experimental ulcerative colitis (UC).Materials and Methods: 5-Aminosalicylic acid-alanine (5-ASA-ALA) was synthesized and characterized. Its stability study was conducted in rat plasma and in the gastroint...

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.

BACKGROUND Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis. AIM To perform a systematic review of the published literature and unpublished randomized clinical trials (RCTs) regarding the impact of non-adherence with 5-ASA m...

New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.

6 Gastroenterology & Hepatology Volume 6, Issue 1, Supplement 1 January 2010 Multiple daily dosing of 5-ASA for UC has been a standard practice since the 1940s. However, these regimens can lead to poor patient adherence. Recently, several 5-ASA formulations have demonstrated non-inferiority to multiple daily dosing, including ethylcellulose-coated microgranules (Pentasa),1 Multi-Matrix delayed ...